ProfileGDS5678 / 1456048_at
TitleAnti-VEGF and Anti-Notch treatment effect on U87 glioblastoma xenograft tumors [Mouse430_2]
OrganismMus musculus


control bevacizumab dibenzazepine GSM967852 GSM967853 GSM967854 GSM967855 GSM967856 GSM967862 GSM967863 GSM967864 GSM967865 GSM967857 GSM967858 GSM967859 GSM967860 GSM967861 18% 19% 19% 19% 19% 22% 19% 19% 18% 19% 19% 19% 19% 19% sort by agent Gene Expression Profile
Graph caption help
SampleTitleValueRank
GSM967852U87-EV human glioblastoma xenograft - Control 12.4712918
GSM967853U87-EV human glioblastoma xenograft - Control 22.4566919
GSM967854U87-EV human glioblastoma xenograft - Control 32.4597819
GSM967855U87-EV human glioblastoma xenograft - Control 42.4150619
GSM967856U87-EV human glioblastoma xenograft - Control 52.4075119
GSM967862U87-EV human glioblastoma xenograft - Bevacizumab treated 12.58422
GSM967863U87-EV human glioblastoma xenograft - Bevacizumab treated 22.4850919
GSM967864U87-EV human glioblastoma xenograft - Bevacizumab treated 32.435319
GSM967865U87-EV human glioblastoma xenograft - Bevacizumab treated 42.4185118
GSM967857U87-EV human glioblastoma xenograft - dibenzazepine treated 12.4484519
GSM967858U87-EV human glioblastoma xenograft - dibenzazepine treated 22.4434919
GSM967859U87-EV human glioblastoma xenograft - dibenzazepine treated 32.4229919
GSM967860U87-EV human glioblastoma xenograft - dibenzazepine treated 42.4484619
GSM967861U87-EV human glioblastoma xenograft - dibenzazepine treated 52.4475119